Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

EClinicalMedicine(2022)10.1016/j.eclinm.2022.101689Source: DataRank Database

A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis is a research paper published in EClinicalMedicine (2022). On theSindex it has a DataRank of 1.1. It has been cited 27 times, with 24 citing works in its 1-hop citation network.

N/A

1.1DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access27 citations · 24 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02776059

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: goldTopics (71)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 47%Citation Network 53%

Base Score Contribution

0.500

From this paper's citation signal

Citation Network Contribution

0.565

From 20 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 24 citers.

G‐ CSF —In Patients With Severe Alcohol‐Associated Hepatitis: A Real‐World Experience
Liver International20248 citations17 referencesContributes 0.129
The Role of Prophylactic Antibiotics for Patients With Severe Alcohol-Related Hepatitis
JAMA20233 citations14 referencesContributes 0.099
Granulocyte Colony Stimulating Factor and Its Combinations With Anti-inflammatory Therapies in Severe Alcoholic Hepatitis: A Systematic Review and Meta-analysis
Journal of Clinical and Experimental Hepatology20252 citations12 referencesContributes 0.092
The role of neutrophils in alcohol-related hepatitis
Journal of Hepatology202355 citations92 referencesContributes 0.044
Current and future treatment for alcoholic‐related liver diseases
Journal of Gastroenterology and Hepatology202316 citations68 referencesContributes 0.042

Authors (28)

Andrew Stolz ORCID,Danh V. Nguyen ORCID,M Wayne Fleischman,John A. Donovan,Joseph Alcorn

Live enrichment

PubMed:36267499 PMC:PMC9576807

National Institute on Alcohol Abuse and Alcoholism

Grant: U01-AA021884

National Institute on Alcohol Abuse and Alcoholism

Grant: U01-AA021886

NIAAA NIH HHS

Grant: U01 AA021886

NCATS NIH HHS

Grant: UL1 TR001414

NIAAA NIH HHS

Grant: U01 AA021884

National Institutes of Health

Grant: 5U01AA021884-03

Southern California Alcoholic Hepatitis Consortium Administrative Core

National Institutes of Health

Grant: 5U01AA021886-02

A prospective, randomized, clinical trial to evaluate two novel therapies, mycoph

goldLicense: cc-by-nc-nd

publisherhttps://doi.org/10.1016/j.eclinm.2022.101689

publisherhttps://api.elsevier.com/content/article/PII:S2589537022004199?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2589537022004199?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9576807

repositoryhttps://doaj.org/article/21ce9efa24d34c9a9784997ac1ab32fa

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

Randomized Clinical TrialPhase IiAlcoholic HepatitisHiv, Human Immunodeficiency VirusFda, Food And Drug AdministrationPegfilgrastimSd, Standard DeviationCtcae, Common Terminology Criteria For Adverse EventsAki, Acute Kidney InjuryWbc, White Blood Cell CountInr, International Normalized RatioSoc, Standard Of CareHrs, Hepatorenal SyndromeAclf, Acute On Chronic Liver FailureDf, Discriminant FunctionGcsf, Granulocyte Colony Stimulating FactorAh, Alcohol-related HepatitisNiaaa, National Institute On Alcohol Abuse And AlcoholismDsmb, Data Safety Monitoring BoardFu, Follow-upMedicine (General)HRSNIAAAalcohol-related hepatitisGCSFDFgranulocyte colony stimulating factorAlcohol Use and HealthSubstance Misusediscriminant functionACLFfollow-upacute on chronic liver failurenational institute on alcohol abuse and alcoholismhepatorenal syndromefood and drug administrationhuman immunodeficiency virusLiver DiseaseSouthern California Alcoholic Hepatitis (SCAH) ConsortiumArticlesAlcoholismacute kidney injurystandard of care6.1 Pharmaceuticalsstandard deviationFDAINRClinical Trials and Supportive Activities610WBCAKIR5-920Clinical Researchdata safety monitoring boardSOCFUDSMBSDPreventioninternational normalized ratiocommon terminology criteria for adverse eventsCTCAEHIVEvaluation of treatments and therapeutic interventionsGood Health and Well BeingAHDigestive Diseaseswhite blood cell count

Sustainable Development Goals

SDG 3: 3. Good health